Cancers 2020, 12 S1 of S2

## **Supplementary Materials: Dopamine D1 Receptor in Cancer**

## Paweł Sobczuk, Michał Łomiak and Agnieszka Cudnoch-Jędrzejewska

**Table S1.** Summary of current data about mRNA and protein expression of type 1 dopamine receptor. Name of cell line or type of examined material is given in brackets.

Cancer Type	D1r Expression	Ref.
Acute T cell leukemia	- protein (Jurkat cells) - present	[107], [110]
Astrocytoma	protein (D384) – present	[167]
Lymphocytes B	-mRNA (DOHH2, H929, KMS11, K1106, K422, LILA OZ, PRI,	[168]
malignancies	RAMOS, REC-1) – present or overexpression	
Cholangiocarcinoma	- mRNA (Mz-ChA-1) - overexpression	[169]
	- mRNA (HuCCT-1, CCLP-1) downregulation	
	- mRNA (SG231) – present	
Colon cancer	- mRNA (HCT116, HT29, RKOp, RKOr1) overexpression	[58,170]
Ependydoma	-protein (patients` samples) – overexpression in 30% cases	[171]
Gist	- protein (patients` samples) - overexpression	[171]
Glioma	- protein (patients samples) - overexpression	[103]
Hepatocellular	- mRNA (Hep3B, patients samples) – upregulation	[58], [172]
carcinoma		
Melanoma	- protein (patients` samples) – overexpression in less than 25%	[171,173]
	cases	
	- lack of mRNA for D1 receptor in cell lines derived from	
	melanoma metastases	
Myelogenous leukemia	- protein (K562) - present	[171]
Neuroblastoma	-protein (NS20Y)	[58,174,175]
	- mRNA (SK-N-MC, SKNSH) - upregulation	
Osteosarcoma	- protein (OS732) - present	[55]
Ovarian cancer	- protein (patients` samples) – overexpression in 50% cases	[171], [23,126]
Pancreatic cancer	- protein (SW1990, patient-derived xenografts) - upregulation	[116]
Pancreatic	mRNA (BON) - present	[176]
neuroendocrine tumor		
Pheochromocytoma	- protein (patients` samples) – overexpression in less than 25%	[171]
	cases	
Renal cell cancer	- protein (patients` samples) – overexpression in 50% cases	[171]
Retinoblastoma	-protein (WERI 27)	[175]
Synovial sarcoma	-protein (patents` samples)- overexpression in 21% cases	[171]
Small cell lung	- protein (patients` samples, patients` derived cell lines, H69) -	[113]
carcinoma	overexpression	

Table S2. Dopamine D1 receptor agonists and antagonists.

	Name	Other information	
Agonists			
6-Br-APB		selective D1 receptor agonist 90-fold selectivity for D1 over D2	
A-68930		selective D1 receptor agonist	
A-77636		selective D1 receptor agonist	
A86929		selective dopamine D1 receptor agonist	

	14-fold selectivity for D <sub>1</sub> -like receptors over D <sub>2</sub>	
dihydrexidine	selective dopamine D1 receptor agonist	
	10-fold selectivity for D <sub>1</sub> -like receptors over D <sub>2</sub>	
dinapsoline	selective dopamine D1 receptor agonist	
	5-fold selectivity for D <sub>1</sub> -like receptors over D <sub>2</sub>	
doxanthrine	dopamine D1 receptor and D2 receptor agonist	
	168-fold greater selectivity for D1 over D2 receptors	
fenoldopam	highly selective peripheral D <sub>1</sub> receptor partial agonist	
PF-06649751	dopamine D1 and D5 receptors partial agonist	
SKF89145	selective D1 receptor agonist	
SKF89626	selective D1 receptor agonist	
SKF38393	very high selectivity for D1 with negligible affinity for any other receptor	
SKF81297	dopamine D1 and D5 receptors agonist	
	200-fold selectivity for D1 over any other receptor	
SKF82958	dopamine D1 and D5 receptors agonist	
	57-fold selectivity for D <sub>1</sub> over D <sub>2</sub>	
stepholidine	D1 agonist and D2 antagonist	
Antagonists		
ecipopam (SCH39166)	D1 and D5 receptors antagonist	
SCH23390	D1 receptor agonist with minimal effect of D2 receptor	



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).